Non-Invasive Coronary Artery Functional Assessment
How this is different
Existing approaches have mostly relied on traditional flow field simulation-based methods. DEEPVESSEL FFR applies Feature Flow®, a proprietary deep learning technology built on the latest advances from the computer vision industry as optimized by our scientific team for medical image analysis. This new approach gives a strong performance advantage with fast processing speed and accurate non-invasive FFR analysis.
In addition to increased processing speed and accuracy, DEEPVESSEL FFR allows clinicians to calculate the FFR value for any location within the coronary artery tree. DEEPVESSEL FFR provides accurate and timely quantitative test results required by clinical practices. This non-invasive analysis of the CTA image is a cost-effective way to determine the most appropriate treatment plan. Some patients may avoid unnecessary catheterization lab procedures. Because non-invasive FFR has clear cost-saving implications, the procedure is covered by government and private insurance in the USA.
Indications for use
CTA scans are increasingly used in the cardiology diagnostic process as a first line tool. Once the image has been acquired, it can be processed in a manner of minutes through DEEPVESSEL FFR to deliver complete non-invasive assessments of coronary artery physiologic function. This makes it attractive for general use, such as during physical examinations, the screening of high-risk populations, the accurate auxiliary diagnosis of suspected patients, and the treatment planning of confirmed patients.
Features of DEEPVESSEL FFR
Non-invasive functional assessment from CTA scan
Enables accurate and fast FFR analysis
Provides both anatomical and functional information
Novel coronary CT FFR technique driven by AI
Reduces medical cost
Advantages of DEEPVESSEL FFR
Input is DICOM files produced from CTA exam.
Results can be delivered in minutes, not hours.
Achieves 89% diagnostic accuracy using invasive FFR as the groundtruth.
Reduces costs from invasive procedure, and unnecessary therapies.
FFR values can be observed at any location in the coronary tree.
Results can be viewed on smart phones, PCs, and tablets.
Clinical Performance Assessment
DEEPVESSEL FFR has been tested via a multi-center prospective clinical trial which recruited patients from Beijing Anzhen Hospital affiliated to Capital Medical University3, Air Force General Hospital PLA, and Cangzhou Central Hospital. DEEPVESSEL FFR analysis results were compared to the invasive FFR values. Additional multi-center clinical trial and performance assessments are underway as in support of the regulatory submissions for approval by the National Medical Products Administration (NMPA) in China.
Product Features of DEEPVESSEL FFR
Functional assessment by DEEPVESSEL FFR
Doctors receive analysis report
Prof. Yujie Zhou
MD. Ph.D., FACC FESC FHRS FSCAI
Vice President, An Zhen Hospital, Capital Medical University, Beijing
“DEEPVESSEL FFR® is undoubtedly an epoch-making product that leads the diagnosis of coronary heart disease from inaccurate to accurate, from invasive to non-invasive. It can not only overcome the deficiencies of the non-invasive diagnosis of coronary heart disease, but also reduce unnecessary invasive testing and costs of patients.”
Prof. William Hau
MD. Ph.D. (Physiology) MSc, BSc (Biomedical Engineering)
Faculty of Medicine, The Chinese University of HongKong
“DEEPVESSEL FFR® is a practical application of the artificial intelligence technology in cardiovascular non-invasive diagnosis. There is no doubt that with the clinical promotion of this product, the work efficiency of the doctor will be highly improved and the medical expenditure of the patients will be reduced.”